Clinical Utility of ¹⁸Fluorine-Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography in the Evaluation of Pancreatic Ductal Adenocarcinoma: Comparison With ¹⁸Fluorine-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is highly susceptible to metastasis, making early detection of metastases and associated risk factors crucial for effective management. This study aimed to assess the performance of ¹⁸fluorine (¹⁸F)- fibroblast activation protein inhibitor-04 (¹⁸F-FAPI-04) positron emission tomography/computed tomography (PET/CT) in detecting metastasis and predicting pathological characteristics and risk factors in 67 PDAC patients. Comparisons were made with ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET/CT. Lesion identifications and radiotracer uptakes were evaluated through visual inspection and semiquantitative analysis using the maximum standardized uptake value (SUVmax). We analyzed the risk factors for metastasis

SUBMITTER: Lin L 

PROVIDER: S-EPMC11891561 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature